QCC374 / Novartis - LARVOL DELTA

Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients (clinicaltrials.gov) - P2; N=5; Terminated; Sponsor: Novartis Pharmaceuticals; Completed ➔ Terminated; Study was terminated early for strategic reasons. Only Part I of the study was completed.

Clinical • Trial termination